Verseon provides an update on preparations for a first-in-human phase I trial in Australia for its lead-PROAC (PRecision Oral AntiCoagulant), VE-1902, which has successfully completed regulatory toxicology studies and was well-tolerated in 28-day repeat dosing. Verseon's PROACs are a novel class of anticoagulants that show efficacy comparable to the NOACs (novel oral anticoagulants) but much-reduced bleeding in preclinical studies. Because of this unique profile, Verseon believes that PROACs could have a major impact on the cardiovascular disease market by becoming the first oral anticoagulants suitable for long-term anticoagulant-antiplatelet combination therapy. This is particularly relevant for the tens of millions of patients worldwide with acute coronary syndrome or non-valvular atrial fibrillation comorbid with coronary artery disease. For the phase I trial of VE-1902, Verseon, through its wholly owned subsidiary VCR1, will submit an application to the Australian Human Research Ethics Committee and expects to initiate participant recruitment shortly after approval by the Therapeutic Goods Administration. To carry out the study, VCR1 is working closely with phase-I unit Nucleus Networks© and full-service contract research organization CPR Pharma Services©. Nucleus Networks© will provide bed space, clinical staff, and sample collection, and CPR Pharma Services© will provide oversight, data management, and biostatistics.